Login to Your Account

Redhill to Start Phase III Trial of Antibiotic Therapy in Crohn's

By Cormac Sheridan
Staff Writer

Tuesday, August 20, 2013

The controversial theory that infection with Mycobacterium avium subspecies paratuberculosis (MAP) is a causative agent in Crohn's disease is about to receive its biggest test yet, as Redhill Biopharma Ltd. initiates a Phase III program involving RHB-104, an antibiotic treatment, in some 600 patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription